First CRISPR Patent in U.S Goes To MilliporeSigma
--Sharing is Caring--

First CRISPR Patent in U.S Goes To MilliporeSigma

MilliporeSigma has bagged the first CRISPR patent in the United States. The U.S. Patent and Trademark Office has issued a formal Notice allowing MilliporeSigma’s application directed to its proxy-CRISPR technology.

MilliporeSigma CEO – Udit Batra in a statement said that this news will be embraced by the researchers in the U.S as numerous gene editing options now exist that can lead to accelerated drug discovery & developments. He further added that MilliporeSigma being a leading innovator of CRISPR Tech with 15 years’ experience in genome editing & discovery- is open to collaborating with scientists globally with an aim to unleash Proxy-CRISPR Tech’s full potential and its ethical usage.

About Proxy-CRISPR, its the latest gene editing technique specifically designed to enhance the efficiency, speed, and specificity of CRISPR tech by nicking the genome for DNA Modification. As MilliporeSigmaper, with the help of this tech, researchers can gain access to regions of the genome that are hard to reach

Proxy-CRISPR by MilliporeSigma utilizes two CRISPR systems developed specifically to act on the genome in proximity to each other. One CRISPR system opens a regional “door,” pushing away blocking chromatin proteins, while the other walks through it to find the exact location for modification. Since this tech involves two CRISPR system, twice the specificity of individual CRISPR system can be achieved.

See Also
Amazon CEO Jeff Bezos Pledges $10 Billion To Fight Climate Change

The U.S. patent allowance marks MilliporeSigma’s 13th CRISPR patent Globally.
The company was granted patents for technologies that were CRISPR-related covering alternative and foundational techniques starting in June 2017 in Australia, two months later in Europe. In Australia and Europe as well as in Canada, MilliporeSigma has received patents for its CRISPR paired nickase technology, which utilizes cleaving opposite strands of a chromosomal order to make a double-stranded fracture –as well as for CRISPR integration technologies, which entails the chromosomal cutting of this sequence of eukaryotic cells and insertion of a DNA sequence.

MilliporeSigma’s CRISPR patent portfolio includes granted patents in Australia, Canada, Europe, Singapore, China, Israel, and South Korea

MilliporeSigma will be licensing its entire patent portfolio for usage in all fields.

As both users and suppliers of genome-editing technology, the businesses of Merck KGaA, Darmstadt, Germany support research with genome editing under careful consideration of ethical and legal standards. Merck KGaA, Darmstadt, Germany has established an independent, external Bioethics Advisory Panel to provide guidance for research in which its businesses are involved, including research on or using genome editing, and has developed, defined and transparently published a clear operational position taking into account scientific and societal issues to inform promising therapeutic approaches for use in research and applications.

See Also
Scientists Turn Human Organs Transparent To Study Cellular Structure

Press Release By MilliporeSigma

Upload Your Resume' / CV to BioTecNika Talent Pool

Download This Notification
Perfection is her hobby, Reliability is a synonym, Editing is her passion, Excellence is her Goal, Tactfulness is in her genes, Yellow is her Fav color. Preety is the name of the Professional on whom entire BioTecNika relies when it comes to its website. A Gold Medalist in Biotech from SRM University, Chennai with a 9.9 CGPA ( was awarded the Gold Medal by Honorable Prime Minister of India Shri Narendra Modi , as seen in the pic ), She decided to join forces with BioTecNika to ensure India's largest BioSciences Portal expands its reach to every city in India. She has redesigned the new avatar of BioTecNika from scratch and heads the most dynamic, vibrant and well informed Online Team at Biotecnika Info Labs Pvt Ltd